Evolent Health, Inc. (NYSE:EVH) CFO John Paul Johnson Sells 44,693 Shares

Evolent Health, Inc. (NYSE:EVH) CFO John Paul Johnson sold 44,693 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total value of $1,340,790.00. Following the sale, the chief financial officer now owns 171,207 shares of the company’s stock, valued at $5,136,210. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Evolent Health Trading Down 4.1 %

NYSE EVH traded down $1.35 on Monday, reaching $31.62. The company had a trading volume of 3,049,630 shares, compared to its average volume of 1,632,854. The stock’s 50 day moving average is $22.48 and its 200-day moving average is $26.55. The stock has a market cap of $3.67 billion, a price-to-earnings ratio of -25.30 and a beta of 1.54. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.57. Evolent Health, Inc. has a 52 week low of $17.98 and a 52 week high of $35.00.

Evolent Health (NYSE:EVH) last released its quarterly earnings data on Thursday, August 8th. The technology company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.09. The business had revenue of $647.10 million during the quarter, compared to the consensus estimate of $636.46 million. Evolent Health had a positive return on equity of 6.90% and a negative net margin of 5.07%. The firm’s revenue was up 37.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.06 earnings per share. Equities analysts predict that Evolent Health, Inc. will post 0.9 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of EVH. Scout Investments Inc. acquired a new position in Evolent Health during the first quarter valued at approximately $5,760,000. Zevenbergen Capital Investments LLC boosted its holdings in shares of Evolent Health by 126.5% in the 1st quarter. Zevenbergen Capital Investments LLC now owns 565,625 shares of the technology company’s stock valued at $18,547,000 after purchasing an additional 315,875 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Evolent Health by 86.7% during the 1st quarter. BNP Paribas Financial Markets now owns 99,126 shares of the technology company’s stock valued at $3,250,000 after acquiring an additional 46,024 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Evolent Health by 11.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 717,334 shares of the technology company’s stock valued at $23,522,000 after acquiring an additional 75,376 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Evolent Health during the 4th quarter valued at $43,759,000.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Canaccord Genuity Group decreased their price objective on Evolent Health from $44.00 to $41.00 and set a “buy” rating for the company in a research report on Friday, May 10th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $42.00 price target on shares of Evolent Health in a research note on Monday. Truist Financial raised Evolent Health from a “hold” rating to a “buy” rating and raised their price target for the stock from $28.00 to $33.00 in a research note on Friday, August 9th. Stephens reaffirmed an “overweight” rating and set a $42.00 price target on shares of Evolent Health in a research note on Tuesday, July 30th. Finally, JPMorgan Chase & Co. raised their price objective on Evolent Health from $36.00 to $45.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. One analyst has rated the stock with a sell rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $40.40.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.